Start-Up Previews (10/2011)
This Month's Profile Group: The New Ophthalmic Drug Players, features profiles of Imagen Biotech, KalVista Pharmaceuticals, ONL Therapeutics and Xcovery Vision. Plus these Start-Ups Across Health Care: Acetylon Pharmaceuticals, Aleva Neurotherapeutics, cermaVEIN and Flex Biomedical.
You may also be interested in...
ONL Therapeutics LLC is developing an experimental drug to preserve sight in people with detached retinas and other retinal disorders. The start-up aims to leverage understanding about FAS, a cell-based receptor that is a key cause of cell death in photoreceptors. ONL’s small peptide is designed to block the FAS receptor on cells of the eye, to keep the natural ligand from binding and keep the cells alive.
Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.
The electrode leads used for deep brain stimulation to treat such conditions as Parkinson’s disease, depression and essential tremors have become a lot smarter, thanks to technology developed by Switzerland’s Aleva Neurotherapeutics SA. The company’s microDBS platform is an evolution of micro-electro-mechanical systems that allows for precise stimulation of targeted brain tissue, leaving the adjacent region unaffected.